Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
11:03 EDT 24 Jul 2012 | Elsevier Business Intelligence
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
Original Article: Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
More From BioPortfolio on "Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
